SpineThera Announces Results for SX600 from its SALIENT Phase 2 Sciatica Pain Clinical Trial Supporting the Potential for Best-In-Class Therapy
Retrieved on:
Wednesday, December 7, 2022
Biotechnology, Pharmaceutical, Physical Therapy, Surgery, General Health, Health, Clinical Trials, Other Health, Physician, Initiative, Patient, Royal Adelaide Hospital, Disability, QOL, Sciatica, Pain, Dexamethasone, WDLP, Quality of life, University, Safety, Oswestry Disability Index, Principal, Medical director, Risk, Pharmaceutical industry, Dentistry, Anesthesia
In total, 56 patients were randomized (17 [SX600 25 mg] 21 [SX600 12.5 mg], 18 [placebo]).
Key Points:
- In total, 56 patients were randomized (17 [SX600 25 mg] 21 [SX600 12.5 mg], 18 [placebo]).
- SX600 has the potential to be a truly meaningful improvement in how we manage our patients suffering with radicular leg pain and the associated functional disability.
- We are delighted with these exciting results and very appreciative of the SpineThera team and SALIENT trial Investigators passion and hard work.
- The companys lead investigational drug product, SX600, is a novel formulation of dexamethasone being developed for the management of sciatica pain.